Ovid returns soticlestat rights in a deal that will fuel its next generation of neuro candidates

Four years after Ovid began leading development of Takeda-partnered epilepsy candidate soticlestat, the biotech is handing back the reins in a deal that will enable it to accelerate development of its preclinical pipeline. 

Ovid Therapeutics Inc. (NASDAQ:OVID) gained $1.08 (36%) to $4.04 on what Chairman and CEO Jeremy Levin told BioCentury was an “unbeatable offer” that will provide Ovid with enough resources to speed progression to IND for its next generation of brain diseases treatments including genetic therapies. ...